Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Suppression of Cdc37 Induces BTZ Resistance through XBP1s Mediated Plasma Cell Immaturation in Multiple Myeloma

Meirong Zang, Lanting LIU, Fengyan Jin, Jiaojiao Guo, An Gang, MD, Xiaoqi Qin, Tao Zhu, Shuhui Deng, Zhang Shuaishuai, MD, Mu Hao, PhD, Xiaoyan Feng, Yan Xu, MD, Wen Zhou, Lugui Qiu, MD

Blood (2017) 130 (Supplement 1): 4350.

https://doi.org/10.1182/blood.V130.Suppl_1.4350.4350

Published: 2017

Journal Articles

Suppression of Cdc37 Induces Bortezomib Resistance through Autophagy Activation and Plasma Cell Immaturation in Multiple Myeloma

Meirong Zang, Fengyan Jin, Lanting Liu, Gang An, MDPhD, Xiaoqi Qin, MD, Xiaoyan Feng, Yan Xu, MDPhD, Mu Hao, MD PhD, Wen Zhou, PhD, Lugui Qiu, MD PhD

Blood (2015) 126 (23): 2480.

https://doi.org/10.1182/blood.V126.23.2480.2480

Published: 2015

Journal Articles

Serum High Expression of Micorna-214 Is a Novel Predictor for Myeloma Bone Disease and Poor Prognosis

Mu Hao, MD PhD, Meirong Zang, PhD, Yan Xu, MDPhD, Yu Qin, MD PhD, Lei Zhao, MD PhD, Shuhui Deng, MD PhD, Weiwei Sui, MD, Gang An, MDPhD, Zengjun Li, MD PhD, Yi Shuhua, MD PhD, Fenghuang Zhan, MD PhD, Lugui Qiu, MD PhD

Blood (2015) 126 (23): 4186.

https://doi.org/10.1182/blood.V126.23.4186.4186

Published: 2015

Journal Articles

Clonal Evolution Paths Significantly Impact the Outcome of Myeloma

Xiaoqi Qin, MD, Gang An, MDPhD, Lin-ping Hu, MD, Yu Qin, MD PhD, Yan Xu, MDPhD, Xiaoyan Feng, Meirong Zang, Shuhui Deng, MD PhD, Weiwei Sui, MD, Shuhua Yi, MD PhD, Zengjun Li, Sr., Lin-hua Yang, MD, Tao Cheng, MD, Jianxiang Wang, MD, Lugui Qiu, MD PhD

Blood (2015) 126 (23): 1784.

https://doi.org/10.1182/blood.V126.23.1784.1784

Published: 2015

Journal Articles

Antitumor Activity of a Novel Proteasome Inhibitor BSc2118 Against Multiple Myeloma

Meirong Zang, PhD, Lanting Liu, Xin Li, Wei Li, MD, Ulrike Kuckelkorn, Wen Zhou, PhD, Lugui Qiu, MD, Fengyan Jin, MD

Blood (2014) 124 (21): 5725.

https://doi.org/10.1182/blood.V124.21.5725.5725

Published: 2014

Journal Articles

Unmeasurable Serum M-Protein Multiple Myeloma Benefit Less from Bortezomib Than Measurable Myeloma

Xiaoqi Qin, Gang An, MD PhD, Yan Xu, MD PhD, Yu Qin, PhD, Xiaoyan Feng, MD, Meirong Zang, PhD, Weiwei Sui, MD, Shuhui Deng, MD, Shuhua Yi, Wen Zhou, PhD, Lugui Qiu, MD

Blood (2014) 124 (21): 2062.

https://doi.org/10.1182/blood.V124.21.2062.2062

Published: 2014

Journal Articles

MiR-137 Contributes to Drug Susceptibility and Chromosomal Instability of Multiple Myeloma through Targeting AURKA

Yu Qin, PhD, Fei Li, MD, Xiaoqi Qin, Gang An, MD PhD, Mu Hao, PhD, Meirong Zang, PhD, Yan Xu, MD PhD, Wen Zhou, PhD, Hong Chang, Lugui Qiu, MD

Blood (2014) 124 (21): 5715.

https://doi.org/10.1182/blood.V124.21.5715.5715

Published: 2014

Journal Articles

Hypermethylation of TAp73 Suppresses ABL1-Involved DNA Damage Response in Multiple Myeloma

Mu Hao, PhD, Yu Qin, PhD, Meirong Zang, PhD, Yan Xu, MD PhD, Gang An, MD PhD, Changhong Li, MD, Ye Yang, PhD, Zhimin Gu, PhD, Fenghuang Zhan, MD PhD, Lugui Qiu, MD PhD

Blood (2014) 124 (21): 3374.

https://doi.org/10.1182/blood.V124.21.3374.3374

Published: 2014

Journal Articles

Clonal Heterogeneityand Evolutional Paths in Multiple Myeloma Revealed By QM-FISH in Single Cell of Sequential Analysis

Xiaoqi Qin, Gang An, MD PhD, Yu Qin, PhD, Yan Xu, MD PhD, Xiaoyan Feng, MD, Meirong Zang, PhD, Weiwei Sui, MD, Shuhui Deng, MD, Shuhua Yi, Wen Zhou, PhD, Lugui Qiu, MD PhD

Blood (2014) 124 (21): 3395.

https://doi.org/10.1182/blood.V124.21.3395.3395

Published: 2014

Journal Articles

Serum Mir-4254, Mir-19a and Mir-33b Are Potential Markers For Diagnosis and Prognostic Evaluation In Multiple Myeloma

Mu Hao, PhD., Meirong Zang, Qin Yu, Li Fei, Wenjuan Yang, Xiaoyan Feng, Fang Qi, Gang An, Changhong Li, Yan Xu, MD., Fenghuang Zhan, MD&PhD, Lugui Qiu, MD

Blood (2013) 122 (21): 3222.

https://doi.org/10.1182/blood.V122.21.3222.3222

Published: 2013

Journal Articles

Epigenetic Silencing Of Mir-137 Contributes To The Proliferation Of Multiple Myeloma By Targeting AURKA

Yu Qin, Fei Li, Gang An, Mu Hao, PhD., Meirong Zang, Lugui Qiu, MD

Blood (2013) 122 (21): 3144.

https://doi.org/10.1182/blood.V122.21.3144.3144

Published: 2013

NARROW

Suppression of Cdc37 Induces BTZ Resistance through XBP1s Mediated Plasma Cell Immaturation in Multiple Myeloma

Suppression of Cdc37 Induces Bortezomib Resistance through Autophagy Activation and Plasma Cell Immaturation in Multiple Myeloma

Serum High Expression of Micorna-214 Is a Novel Predictor for Myeloma Bone Disease and Poor Prognosis

Clonal Evolution Paths Significantly Impact the Outcome of Myeloma

Antitumor Activity of a Novel Proteasome Inhibitor BSc2118 Against Multiple Myeloma

Unmeasurable Serum M-Protein Multiple Myeloma Benefit Less from Bortezomib Than Measurable Myeloma

MiR-137 Contributes to Drug Susceptibility and Chromosomal Instability of Multiple Myeloma through Targeting AURKA

Hypermethylation of TAp73 Suppresses ABL1-Involved DNA Damage Response in Multiple Myeloma

Clonal Heterogeneityand Evolutional Paths in Multiple Myeloma Revealed By QM-FISH in Single Cell of Sequential Analysis

Serum Mir-4254, Mir-19a and Mir-33b Are Potential Markers For Diagnosis and Prognostic Evaluation In Multiple Myeloma

Epigenetic Silencing Of Mir-137 Contributes To The Proliferation Of Multiple Myeloma By Targeting AURKA

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only